Company news
Travere Therapeutics, Inc. news in 2022
Travere Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
November 14, 2022
Travere Therapeutics Reports Third Quarter 2022 Financial Results
October 26, 2022
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
October 25, 2022
Travere Therapeutics to Report Third Quarter 2022 Financial Results
October 19, 2022
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
October 12, 2022
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
August 24, 2022
Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy
August 21, 2022
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
August 21, 2022
Travere Therapeutics Reports Second Quarter 2022 Financial Results
August 3, 2022
Travere Therapeutics Provides Regulatory Updates on its Development Programs
August 2, 2022
Travere Therapeutics to Report Second Quarter 2022 Financial Results
July 27, 2022
Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference
June 1, 2022
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
May 16, 2022
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
May 15, 2022
Travere Therapeutics Reports First Quarter 2022 Financial Results
May 4, 2022
Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
May 2, 2022
Travere Therapeutics to Report First Quarter 2022 Financial Results
April 27, 2022
Travere Therapeutics Announces Plan for Chief Financial Officer Transition
April 19, 2022
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022
April 5, 2022
Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
March 20, 2022
Travere Prices Upsized $275 Million Convertible Senior Notes Offering
March 7, 2022
Travere Announces Proposed Convertible Senior Notes Offering
March 7, 2022
Travere Therapeutics to Present at the Barclays Global Healthcare Conference
March 2, 2022
Travere Therapeutics Recognizes Rare Disease Day 2022 and Raises Awareness for People Living with Rare Disease
February 27, 2022
Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
Travere Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results
February 9, 2022
Travere Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 8, 2022
Travere Therapeutics Provides Corporate Update and 2022 Outlook
January 9, 2022
Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer
January 3, 2022
Calls in 2022
- Travere Therapeutics (NASDAQ:TVTX) Q3 2022 Earnings Call
Oct 27, 2022
Transcript - Travere Therapeutics (NASDAQ:TVTX) Q2 2022 Earnings Call
Aug 4, 2022
Transcript - Travere Therapeutics (NASDAQ:TVTX) Q1 2022 Earnings Call
May 5, 2022
Transcript - Travere Therapeutics (NASDAQ:TVTX) Q4 2021 Earnings Call
Feb 24, 2022
Transcript